Current Opinion in Pharmacology最新文献_第10页

Anabolic–androgenic steroid abuse and testicular function in men; recent insights 男性合成代谢雄激素类固醇滥用与睾丸功能的关系最近的见解

IF 4 3区医学

Current Opinion in Pharmacology Pub Date : 2022-12-01 DOI: 10.1016/j.coph.2022.102318

Willem de Ronde , Diederik L. Smit

引用次数: 2

Hormonal drugs for the treatment of endometriosis 治疗子宫内膜异位症的激素药物

IF 4 3区医学

Current Opinion in Pharmacology Pub Date : 2022-12-01 DOI: 10.1016/j.coph.2022.102311

Tommaso Capezzuoli, Margherita Rossi, Francesco La Torre, Silvia Vannuccini, Felice Petraglia

{"title":"Hormonal drugs for the treatment of endometriosis","authors":"Tommaso Capezzuoli, Margherita Rossi, Francesco La Torre, Silvia Vannuccini, Felice Petraglia","doi":"10.1016/j.coph.2022.102311","DOIUrl":"10.1016/j.coph.2022.102311","url":null,"abstract":"<div>In the past, the primary approach for the treatment of endometriosis was represented by surgery; however, after the introduction of non-invasive diagnosis of endometriosis with the development of imaging technologies, medical treatment became the preferred approach, particularly in young patients. Hormonal drugs, by blocking menstruation, are the most effective for the treatment of endometriosis-related pain, independently of phenotype (ovarian, deep, or superficial endometriosis).Gonadotropin-releasing hormone analogs and oral antagonists act on hypothalamus-pituitary-ovary axis inducing iatrogenic menopause, thus reducing dysmenorrhea and all pain symptoms. The side effects, such as hot flushes and bone loss, may be reduced by an add-back therapy. However, the cost in terms of women's health remains high in view of a long-term treatment.Progestins are considered the first-line treatment, highly effective, and with reduced side effects. In addition to the well-known and largely used Norethisterone acetate and Medroxyprogesterone acetate, recently Dienogest has become one of the most used drugs in all endometriosis phenotypes for long-term treatment. Besides, Intrauterine levornogestrel or subcutaneous etonogestrel are valid alternative for long-term treatment.</div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"67 ","pages":"Article 102311"},"PeriodicalIF":4.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10565067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Current and emerging biologic and small molecule systemic treatment options for psoriasis and psoriatic arthritis 银屑病和银屑病关节炎当前和新兴的生物和小分子系统治疗方案

IF 4 3区医学

Current Opinion in Pharmacology Pub Date : 2022-12-01 DOI: 10.1016/j.coph.2022.102292

Christine P. Lin , Joseph F. Merola , Elizabeth B. Wallace

引用次数: 4

Current treatment and molecular targets for axial spondyloarthritis: Evidence from randomized controlled trials 轴性脊柱炎的当前治疗和分子靶点:来自随机对照试验的证据

IF 4 3区医学

Current Opinion in Pharmacology Pub Date : 2022-12-01 DOI: 10.1016/j.coph.2022.102307

Rouhin Sen , Liron Caplan

引用次数: 2

Targeting fibroblast-like synoviocytes in rheumatoid arthritis 类风湿关节炎靶向成纤维细胞样滑膜细胞

IF 4 3区医学

Current Opinion in Pharmacology Pub Date : 2022-12-01 DOI: 10.1016/j.coph.2022.102304

Vladislav Tsaltskan, Gary S. Firestein

引用次数: 12

Editorial overview – 2022 respiratory issue: Cystic fibrosis pathophysiology, models, and novel therapies 编辑概述- 2022呼吸问题:囊性纤维化病理生理学，模型和新疗法

IF 4 3区医学

Current Opinion in Pharmacology Pub Date : 2022-12-01 DOI: 10.1016/j.coph.2022.102289

Carla M.P. Ribeiro, Martina Gentzsch

引用次数: 0

Ubiquitin proteasome system in immune regulation and therapeutics 泛素蛋白酶体系统在免疫调节和治疗中的应用

IF 4 3区医学

Current Opinion in Pharmacology Pub Date : 2022-12-01 DOI: 10.1016/j.coph.2022.102310

Sameer Ahmed Bhat, Zahra Vasi, Ritika Adhikari, Anish Gudur, Asceal Ali, Liping Jiang, Rachel Ferguson, David Liang, Shafi Kuchay

{"title":"Ubiquitin proteasome system in immune regulation and therapeutics","authors":"Sameer Ahmed Bhat, Zahra Vasi, Ritika Adhikari, Anish Gudur, Asceal Ali, Liping Jiang, Rachel Ferguson, David Liang, Shafi Kuchay","doi":"10.1016/j.coph.2022.102310","DOIUrl":"10.1016/j.coph.2022.102310","url":null,"abstract":"<div>The ubiquitin proteasome system (UPS) is a proteolytic machinery for the degradation of protein substrates that are post-translationally conjugated with ubiquitin polymers through the enzymatic action of ubiquitin ligases, in a process termed ubiquitylation. Ubiquitylation of substrates precedes their proteolysis via proteasomes, a hierarchical feature of UPS. E3-ubiquitin ligases recruit protein substrates providing specificity for ubiquitylation. Innate and adaptive immune system networks are regulated by ubiquitylation and substrate degradation via E3-ligases/UPS. Deregulation of E3-ligases/UPS components in immune cells is involved in the development of lymphomas, neurodevelopmental abnormalities, and cancers. Targeting E3-ligases for therapeutic intervention provides opportunities to mitigate the unintended broad effects of 26S proteasome inhibition. Recently, bifunctional moieties such as PROTACs and molecular glues have been developed to re-purpose E3-ligases for targeted degradation of unwanted aberrant proteins, with a potential for clinical use. Here, we summarize the involvement of E3-ligases/UPS components in immune-related diseases with perspectives.</div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"67 ","pages":"Article 102310"},"PeriodicalIF":4.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9768948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Tapering biologic DMARDs in rheumatoid arthritis 逐渐减少类风湿性关节炎的生物dmard

IF 4 3区医学

Current Opinion in Pharmacology Pub Date : 2022-12-01 DOI: 10.1016/j.coph.2022.102308

Genna Braverman , S. Louis Bridges , Larry W. Moreland

{"title":"Tapering biologic DMARDs in rheumatoid arthritis","authors":"Genna Braverman , S. Louis Bridges , Larry W. Moreland","doi":"10.1016/j.coph.2022.102308","DOIUrl":"10.1016/j.coph.2022.102308","url":null,"abstract":"<div>With the arrival of biologics and the shift toward treat-to-target therapy, the possibility of a sustained clinical response has become an achievable goal for many patients with rheumatoid arthritis (RA). Although biologics have revolutionized the treatment of RA, they are costly, potentially inconvenient, and carry risks of side effects. Whether they can or should be tapered in patients with tight disease control is a matter of clinical uncertainty. The major international rheumatology professional societies have all issued guidelines on this question, but across recommendations, consensus is lacking on how and when to consider therapy de-escalation. Recent evidence suggests that sustained remission or low disease activity is more attainable with dose reduction as opposed to outright discontinuation of biologic therapy, and certain predictors of successful taper have begun to be described. This article will (1) summarize the current evidence base for biologic tapering in RA, (2) outline real-world outcomes findings, (3) review important contextual factors relevant to therapy de-escalation, such as cost-effectiveness considerations and patient perspectives, and (4) conclude by summarizing current guidelines.</div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"67 ","pages":"Article 102308"},"PeriodicalIF":4.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10576425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Editorial overview: Introduction to the musculoskeletal section of current opinion in pharmacology 编辑综述：药理学当前观点的肌肉骨骼部分介绍。

IF 4 3区医学

Current Opinion in Pharmacology Pub Date : 2022-12-01 DOI: 10.1016/j.coph.2022.102306

Christopher P. Cardozo, Helen Bramlett

引用次数: 0

Novel therapeutic avenues for kisspeptin kisspeptin的新治疗途径

IF 4 3区医学

Current Opinion in Pharmacology Pub Date : 2022-12-01 DOI: 10.1016/j.coph.2022.102319

Jovanna Tsoutsouki , Ali Abbara , Waljit Dhillo

{"title":"Novel therapeutic avenues for kisspeptin","authors":"Jovanna Tsoutsouki , Ali Abbara , Waljit Dhillo","doi":"10.1016/j.coph.2022.102319","DOIUrl":"10.1016/j.coph.2022.102319","url":null,"abstract":"<div>Kisspeptin is a hypothalamic neuropeptide that acts via the hypothalamus to stimulate hypothalamic gonadotrophin-releasing hormone secretion and downstream gonadotrophin release. In health, kisspeptin induces normal puberty and modulates ovulation in healthy women. Hypothalamic kisspeptin expression is reduced in several functional reproductive disorders; thus, treating such conditions with kisspeptin is conceptually attractive. Recent studies have demonstrated that kisspeptin can induce a more physiological degree of oocyte maturation during in vitro fertilisation treatment that can reduce the risk of potentially life-threatening complications such as ovarian hyperstimulation syndrome seen with human chorionic gonadotrophin. Furthermore, chronic use of kisspeptin could potentially restore reproductive health in females with hypothalamic amenorrhoea, treat hyposexual drive disorder in otherwise healthy males and has potential indications in polycystic ovary syndrome, osteoporosis and metabolic dysfunction-associated fatty liver disease. Finally, kisspeptin analogues could potentially overcome some of the pharmacological challenges associated with the natural forms of kisspeptin such as short duration of action and development of tachyphylaxis.</div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"67 ","pages":"Article 102319"},"PeriodicalIF":4.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10576953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5